The restructuring events database contains factsheets with data on large-scale restructuring events reported in the principal national media and company websites in each EU Member State. This database was created in 2002.
Manufacturing Manufacture Of Chemicals And Pharamceuticals Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations 21.2 - Manufacture of pharmaceutical preparations
2,000 jobs Number of planned job creations
Announcement Date
10 September 2022
Employment effect (start)
10 September 2022
Foreseen end date
10 September 2024
Description
As announced on 8 September 2022, the German pharmaceutical company BioNTech will be expanding its workforce by approximately 2,000 within the next years. BioNTech intends to increase its workforce at its headquarters in Mainz from 3,000 to 5,000 employees. The company is currently expanding its research and production facilities in Mainz and intends to invest several billion euros within in the next years.
Additionally, BioNTech intends to create new Jobs in Marburg. However, there are currently no information on number of jobs nor a timeframe available.
Sources
10 September 2022: Die Welt (online) (www.welt.de)
Eurofound (2022), BioNTech, Business expansion in Germany, factsheet number 107301, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/107301.
Digitisation and automation technologies, including artificial intelligence (AI), can affect working conditions in a variety of ways and their use in the workplace raises a host of new ethical concerns.
The retail banking sector is fertile ground for studying the impacts of digitalisation on work and employment. Financial services are increasingly provided online, without the intermediary of customer-facing institutions.
European labour markets have recovered strongly from COVID-19. By the end of 2021, little more than 18 months after the start of the pandemic, employment rates in the EU were almost at pre-crisis levels.
